Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School of Southeast University, Nanjing, People's Republic of China; Collaborative Innovation Center of Suzhou Nano-Science and Technology, Suzhou Key Laboratory of Biomaterials and Technologies, Suzhou, People's Republic of China; Nanjing Drum Tower Hospital, Medical School of Nanjing University, Nanjing, People's Republic of China.
Nanjing Drum Tower Hospital, Medical School of Nanjing University, Nanjing, People's Republic of China.
Cancer Treat Rev. 2019 Mar;74:49-60. doi: 10.1016/j.ctrv.2018.08.006. Epub 2018 Aug 20.
Immune checkpoint inhibitors-based immunotherapy offers a new effective modality in the treatment of advanced malignancies. Considering the remarkable efficacy of immune checkpoint inhibitors in clinical trials, the FDA has approved a variety of immune checkpoint inhibitors for the treatment of advanced tumors. However, only limited patients with certain cancers can benefit from monotherapy of immune checkpoint inhibitors. Interventional therapy for cancer can not only destroy the primary tumors, but also regulate the immune system through different mechanisms, which provides a potential possibility for the combination of immune checkpoint inhibitors and interventional modalities in cancer treatment. This article reviews the possible synergistic mechanisms of interventional therapy combined with immune checkpoint inhibitors and summarizes the research progress of the combined therapy in cancer treatment.
免疫检查点抑制剂为治疗晚期恶性肿瘤提供了一种新的有效方法。鉴于免疫检查点抑制剂在临床试验中的显著疗效，FDA 已批准多种免疫检查点抑制剂用于治疗晚期肿瘤。然而，只有有限的特定癌症患者可从免疫检查点抑制剂单药治疗中获益。癌症介入治疗不仅可以破坏原发肿瘤，还可以通过不同机制调节免疫系统，这为免疫检查点抑制剂与介入方式联合应用于癌症治疗提供了潜在可能性。本文综述了介入治疗联合免疫检查点抑制剂的可能协同作用机制，并总结了该联合治疗方案在癌症治疗中的研究进展。
Int Immunopharmacol. 2018-7-2
J Cell Biol. 2019-2-13
Ann Oncol. 2017-2-1
Cell Oncol (Dordr). 2019-6-14
Urol Oncol. 2016-12
Int J Mol Sci. 2019-1-4
Nat Commun. 2020-7-30
Zotero 插件